A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Phase of Trial: Phase II
Latest Information Update: 11 Mar 2018
At a glance
- Drugs Duvelisib (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Verastem
- 22 Feb 2018 Status changed from not yet recruiting to recruiting.
- 07 Dec 2017 Status changed from planning to not yet recruiting.
- 09 Sep 2017 New trial record